HAPLN3

Across TCGA pan-cancer cohorts, HAPLN3 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated HAPLN3 data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher HAPLN3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated HAPLN3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

COAD, SKCM, and UCEC are the cancer types where HAPLN3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	All	0.228	0.797	<.001	30	view →
SKCM	DFS	Median	IV	0.016	0.454	<.001	6	view →
UCEC	DFS	Median	All	0.955	0.621	.030	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

HAPLN3–COAD (DFS)

Open the COAD breakdown →